# FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer

> **NCT02063529** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 101 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** FOLFOXIRI + Cetuximab
- **DRUG:** FOLFOXIRI

## Key facts

- **NCT ID:** NCT02063529
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2020-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02063529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02063529, "FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02063529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*